Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Liabilities and Shareholders Equity (2016 - 2025)

AC Immune (ACIU) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $263.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 27.9% to $263.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $946.2 million, a 0.05% change, with the full-year FY2024 number at $263.6 million, up 29.5% from a year prior.
  • Liabilities and Shareholders Equity was $263.6 million for Q4 2024 at AC Immune, up from $206.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $283.5 million in Q4 2021 to a low of $193.0 million in Q4 2022.
  • A 5-year average of $242.1 million and a median of $263.6 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 31.93% in 2022, then rose 27.9% in 2024.
  • AC Immune's Liabilities and Shareholders Equity stood at $264.1 million in 2020, then increased by 7.37% to $283.5 million in 2021, then plummeted by 31.93% to $193.0 million in 2022, then grew by 6.78% to $206.1 million in 2023, then rose by 27.9% to $263.6 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Liabilities and Shareholders Equity are $263.6 million (Q4 2024), $206.1 million (Q4 2023), and $193.0 million (Q4 2022).